Tecovirimat Intravenous Treatment for Orthopox Virus Exposure

* To provide a therapeutic option for patients not able to take the oral formulation of TPOXX (e.g., cannot swallow, vomiting) and who have confirmed or suspected (based on clinical signs and symptoms with known exposure while laboratory confirmation may be pending) orthopox virus infections OR who have a significant vaccinia adverse reaction (as defined in the protocol) resulting from vaccinia vaccination, secondary transmission, or other exposure; * To collect data on the safety of TPOXX IV (tecovirimat injection, 10 mg/mL).